GENMAB AS DK 1/ DK0010272202 /
12/23/2024 7:35:12 PM | Chg. +3.95 | Volume | Bid8:59:43 PM | Ask8:59:43 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
198.70EUR | +2.03% | 0 Turnover: 0.00 |
-Bid Size: - | -Ask Size: - | 13.15 bill.EUR | - | - |
GlobeNewswire
8/19
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...
GlobeNewswire
6/28
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...
GlobeNewswire
4/30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
4/3
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
10/17/2023
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
9/25/2023
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire
9/4/2023
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire
10/19/2021
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021